Betahistindihydrochlorid
BETAHISTINE HYDROCHLORIDE · Betahistine Di HCl · PT-9 · Serc · Betaserc · Microser · SinMenier · BetahistineHCl
Identifikatoren & physikalische Daten
| CAS No. | 5579-84-0 |
|---|---|
| Summenformel | C8H14Cl2N2 |
| Durchschnittliche Molmasse | 209,11 g/mol |
| Monoisotopische Masse | 208,0534038 g/mol |
| SMILES | CNCCc1ccccn1.Cl.Cl |
| InChIKey | XVDFMHARQUBJRE-UHFFFAOYSA-N |
| PubChem CID | 68643 |
| ChEMBL | CHEMBL1446813 |
| EC No. | 226-966-5 |
| DTXSID | DTXSID10204355 |
| Lokaler Name | Betahistindihydrochlorid |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 24,9 |
|---|---|
| H-Brücken-Donoren | 3 |
| H-Brücken-Akzeptoren | 2 |
| Frei drehbare Bindungen | 3 |
| Schwere Atome | 12 |
| Formalladung | 0 |
| Komplexität | 83,3 |
| Schmelzpunkt | 150-154 °C |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | Very soluble in water, soluble in ethanol (96 per cent), practically insoluble in 2propanol. |
| Aggregatzustand | powder |
| Farbe | Pale Yellow |
| Stabilität | Hygroscopic |
| InChI | InChI=1S/C8H12N2.2ClH/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H32*1H |
| InChIKey | XVDFMHARQUBJRE-UHFFFAOYSA-N |
| SMILES | C1(CCNC)=NC=CC=C1.Cl.Cl |
| CAS Datenbank | 5579-84-0(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 1.8% (1 of 55) of reports.WarningH315 (94.5%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P273, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 55 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Weitere Sicherheitsinformationen | IMAP assessments - 2-Pyridineethanamine, N-methyl-, dihydrochloride: Environment tier I assessment |
| Hazard Classes and Categories | Skin Irrit. 2 (94.5%) |
| Wassergefährdungsklasse (WGK) | 3 |
| Zollcode | 29333990 |
| RTECS-Nr. | UT2969000 |
| Sicherheitshinweise (S) | 24/25 |
| Lagerklasse | 11 - Combustible Solids |
Anwendungen & Verwendung
Beschreibung
Betahistine dihydrochloride (BH.2HCl) is an orally active histamine analog which has been used to control vertigo, lack of hearing and tinnitus related to Ménière’s disease. The mechanism of BH.2HCl is to reduce the pressure of the membranous labyrinth that results in enhancement of the microvasculature circulation and improves the signs of Ménière’s disease. Peroral administration undergoes extensive first-pass metabolism and gastric irritation in patients with peptic ulcer. In treatment of vertigo, a uniform and constant supply of drug is required in order to maintain steady-state concentration of the drug in the body. Unfortunately, BH.2HCl possesses a short half-life of about 3–4 h and requires frequent administration of the drug,12–15 thereby making it an ideal candidate for controlled release preparations.
Verwenden
Betahistine is belongs to a group of medications used to treat vertigo associated with Ménière's disease. Vertigo is a condition that causes sufferers to have a sensation of rotation or movement of themselves or their surroundings. Ménière's disease is a disorder of the inner ear that causes vertigo in addition to symptoms such as ringing in the ears, headache, and loss of hearing.Betahistine is used to reduce the number of episodes of vertigo associated with Ménière's disease. It is believed to work by decreasing the pressure in the ear. This pressure is believed to contribute to the sense of dizziness, nausea, and ringing in the ears and hearing loss that people with Ménière's disease experience.